Home / Archive / August 2011

August 2011 Volume 7, Issue 8

Volume 7, Issue 8 | August 2011

In this Issue

Research & Development

A toothsome BiTE

Micromet inks cancer drug deal with Amgen that could be worth just over $1 billion

A 'killer' combination

BMS, Innate Pharma collaborate on NK cell-activating antibody

Seen but not heard

Sanofi and Audion Therapeutics quietly partner on potential treatments for hearing loss

Gilead pursues ‘one-a-day’ HIV pill

Biopharma teams up with J&J to fight virus that causes AIDS

From Boston to Brussels

Belgium’s UCB launches research alliance with Harvard University

Getting in the zone

BioZone Pharma acquires BioZone Labs, related companies for 21 million stock shares

Crucell, Scripps researchers find broadly acting flu antibody

Discovery of natural antibody could bring universal flu vaccine a step closer

Global News

Royal wedding

Royalty Pharma adds an Astellas brand to its big-name portfolio

Worth weighting for?

Zealand Pharma and Boehringer Ingelheim to work on novel compounds to treat type 2 diabetes and obesity

Russian toward innovation

Pfizer and ChemRar High Tech Center to explore innovative medical R&D partnership in Russia

Bridging the industry-academia gap

Canada's Centre for Drug Research and Development teams up with Germany's Lead Discovery Center to use basic research to develop 'promising innovations' for several diseases

Eyeing a bright future

MingSight, Relin form joint venture in China to develop novel treatment for diabetic eye disease

Harvard Bioscience acquires CMA Microdialysis' preclinical business

Harvard Bioscience Inc., a global developer of tools for life science research and regenerative medicine, announced last month that it has acquired the preclinical business unit of CMA Microdialysis AB through a purchase of assets.

Contract Services

Skin is in for Valeant

Canadian pharma snags dermatology assets with two acquisitions totaling $770 million

NexACT for Apricus, BioTox

Apricus Biosciences sells Bio-Quant CRO subsidiary to BioTox Sciences; both companies shift focus

Quintiles and the Queen

The company’s prime site program goes live at Queen Mary University, aims to accelerate clinical research

AMRI and Proteros Biostructures announce strategic alliance

Combination of structural biology services and drug discovery capabilities aims to provide 'integrated solutions from one point of service and contact'

Try it, you'll like it!

After a months-long collaboration, CanAm Bioresearch and EpiTherapeutics sign a formal medicinal chemistry research agreement

ICON acquires Firecrest Clinical

Omics & Systems Biology

On the trail of oncology biomarkers

Evotec-Roche collaboration to focus on identifying protein-phosphorylations

Finding GEMS

AstraZeneca, PTC Therapeutics announce strategic oncology drug discovery collaboration

Two heads are better than one

LGC’s Genomics division combines with KBioscience with aim of creating a market leading genomics position

Banking on biotherapeutics

Promega partners with ATCC to offer new cell systems for biologics drug discovery

An ‘aha’ moment

University of Colorado School of Medicine seeks funding for $5 million clinical trial for drug to halt progression of Parkinson\'s disease

Proteome Sciences and Moffitt Cancer Center collaborate on clinical mass spec assays for assessment of cancer patien

Proteome Sciences PLC, a global leader in applied proteomics and peptidomics, has entered into a collaboration agreement with the renowned Moffitt Cancer Center to develop mass spectrometry assays measuring certain key signaling and repair pathway proteins that can be adapted for tumor biopsy analysis in the clinic.

Commentary

The changing face of regulatory outsourcing

In a supercharged business and regulatory climate, life sciences companies large and small are turning to outsourcing vendors to manage tactical tasks and help them adopt best practices.

So many innovation strategies …

In the last month or so, I’ve read white papers, CEO speeches, editorials and op-eds in response to what some now call a crisis in innovation, perhaps to mirror the purported crisis in education.

Editor's Focus

Embryonic stem cell research: A Dickey-Wicker of a situation

Isn’t it about time Congress revisited what is essentially an afterthought on a 15-year-old appropriations bill, clearly articulated the facts and concerns about hESC research and put forth a specific policy on the matter?

Special Reports

ddn Editorial Roundtable: Ethics and stem cell research

Researchers discuss the ethical, moral and scientific concerns associated with stem cell research

Root to stem

In new survey, we try to get to the bottom of perceptions on stem cells and other R&D efforts

Instruments & Informatics

Molecular Devices snaps up Genetix

Genetix products are cited as key to the transaction

A capital transaction

Berlin's Eckert & Ziegler acquires the analytic instrumentation and radiochemistry equipment business from Washington, D.C.-based Bioscan

Swiss design and Arizona necessity converge

Tecan collaborates with TGen and ASU Biodesign Institute on comprehensive sample preparation solution for proteomic research

Terminating NGS data hassles

LaserGen, National Instruments collaborate to improve accuracy of DNA sequencing

SANYO and BD Biosciences collaborate on life sciences tools

SANYO North America Corp.’s Biomedical Solutions Division and BD Biosciences, a segment of Becton, Dickinson and Co., last month announced a strategic agreement to jointly promote cutting-edge life science research tools designed to advance cell culture and cell therapy research.

August 2011